A post-reaction regimen for CRC patients manifesting hypersensitivity to oxaliplatin : an effective alternative not to rule out an important option of treatmentC. Nisi, Antonio Frassoldati, Donatella Donati et al.|Annals of Oncology|2015Cited by 1
Can irinotecan dose reduction according to ugt1a1 genotype avoid severe toxicities?Francesca Daniel, Antonio Frassoldati, Lorenzo Belluomini et al.|Annals of Oncology|2016Cited by 1
The regorafenib issue: focus on efficacy and safety in pre-treated metastatic colorectal cancer from a real world experienceFrancesca Daniel, Antonio Frassoldati, E. Bannò et al.|Annals of Oncology|2017Cited by 1
Estrogen receptor mutation: a new strategy to overcome endocrine resistanceAndrea Moretti, Antonio Frassoldati, I. Toma et al.|Annals of Oncology|2017Cited by 1